Phase II study of glofitamab in patients with R/R LBCL
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2022-06-14
Просмотров: 508
Описание: Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the design and results of the pivotal Phase II trial evaluating glofitamab in patients with relapsed/refractory (R/R) aggressive large B-cell lymphoma (LBCL) who have been treated with CAR-T therapy (NCT03075696). The trial reported high and durable complete remission rates. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке: